https://scholars.lib.ntu.edu.tw/handle/123456789/458770
標題: | Comparative analysis between radical cystectomy and trimodality therapy for clinical Stage II Bladder Cancer: Experience from a tertiary referral center | 作者: | JIAN-HUA HONG Lin Y.-H. YU-CHUAN LU YUN CHIANG Tai H.-C. KUO-HOW HUANG CHIA-HSIEN CHENG YEONG-SHIAU PU |
公開日期: | 2018 | 卷: | 29 | 期: | 1 | 起(迄)頁: | 25-32 | 來源出版物: | Urological Science | 摘要: | Objectives: To analyze the clinicopathologic characteristics and oncologic outcomes between radical cystectomy (RC) and trimodality therapy (TMT) for patients with clinical stage II bladder urothelial carcinoma (UC). Methods: Between January 2004 and September 2013, the medical records of 93 consecutive patients with clinical stage II bladder cancer (cT2N0M0) diagnosed at National Taiwan University Hospital were retrospectively reviewed, including 66 with RC and 27 with TMT. Univariate and multivariate Cox regression analyses were performed to determine prognostic factors. Results: The median follow-up time was 34.1 months. There were no significant differences between the TMT and RC group with respect to age, gender, cancer grade and the presence of hydronephrosis. The 5-year overall survival rate (74%) and the 5-year cancer specific survival rate (76%) showed comparable results between RC and TMT group. The overall recurrence rate was 38 % (RC: 41% vs. TMT: 30%, p=0.35). Presence of hydronephrosis demonstrated statistically significant association with tumor recurrence (HR: 2.05, 95% CI 1.04-4.04, p=0.04). Patients with diabetes mellitus (DM) were independently correlated with poorer overall survival (HR: 2.73, 95% CI 1.09-6.82, p= 0.03) and cancer-specific survival (HR: 3.32, 95% CI 1.28-8.65, p= 0.01.) Conclusions: TMT is an optimal therapeutic option in selected patients with clinical stage II bladder UC. In our study, despite the method of treatment, presence of hydronephrosis increased cancer recurrence risk and DM demonstrated a significantly negative effect on overall survival and cancer-specific survival. ? 2018 Urological Science | Published by Wolters Kluwer - Medknow. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/458770 | DOI: | 10.4103/UROS.UROS-13-17 | SDG/關鍵字: | antineoplastic agent; adult; aged; anemia; Article; bladder cancer; cancer chemotherapy; cancer patient; cancer radiotherapy; cancer recurrence; cancer specific survival; cancer staging; cancer surgery; cancer trimodality therapy; cohort analysis; controlled study; cystectomy; diabetes mellitus; female; fever; gastrointestinal toxicity; human; hydronephrosis; leukopenia; major clinical study; male; nausea; overall survival; patient selection; priority journal; recurrence risk; retrospective study; survival rate; tertiary care center; thrombocytopenia; urogenital tract disease; vomiting |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。